Comprehensive Stock Comparison
Compare Ardelyx, Inc. (ARDX) vs ADMA Biologics, Inc. (ADMA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ADMA | 65.2% revenue growth vs ARDX's 22.1% |
| Value | ADMA | Lower P/E (16.3x vs 401.8x) |
| Quality / Margins | ADMA | 42.9% net margin vs ARDX's -14.2% |
| Stability / Safety | ARDX | Beta 0.62 vs ADMA's 1.10 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ARDX | +22.2% vs ADMA's -5.0% |
| Efficiency (ROA) | ADMA | 36.8% ROA vs ARDX's -11.6%, ROIC 37.7% vs -10.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Ardelyx is a biopharmaceutical company that develops and commercializes novel medicines for gastrointestinal and cardiorenal diseases. It generates revenue primarily from sales of its FDA-approved drug tenapanor — marketed as IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for hyperphosphatemia in chronic kidney disease patients — along with partnership milestone payments and royalties from international licensing deals. The company's competitive advantage lies in its proprietary NHE3 inhibitor technology platform, which enables development of first-in-class oral therapies targeting specific ion transport pathways with potentially better safety profiles than existing treatments.
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases. It generates revenue primarily from sales of its intravenous immune globulin products — BIVIGAM and ASCENIV — along with its Hepatitis B treatment Nabi-HB, while also operating plasma collection facilities. The company's key advantage is its integrated business model that combines plasma collection, manufacturing, and commercialization, creating a vertically controlled supply chain for plasma-derived therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ADMA leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). ARDX leads in 2 (Valuation Metrics, Risk & Volatility).
Financial Metrics (TTM)
ADMA and ARDX operate at a comparable scale, with $489M and $398M in trailing revenue. ADMA is the more profitable business, keeping 42.9% of every revenue dollar as net income compared to ARDX's -14.2%.
| Metric | ARDXArdelyx, Inc. | ADMAADMA Biologics, I… |
|---|---|---|
| RevenueTrailing 12 months | $398M | $489M |
| EBITDAEarnings before interest/tax | -$35M | $175M |
| Net IncomeAfter-tax profit | -$57M | $209M |
| Free Cash FlowCash after capex | -$55M | $41M |
| Gross MarginGross profit ÷ Revenue | +88.9% | +54.7% |
| Operating MarginEBIT ÷ Revenue | -9.5% | +34.2% |
| Net MarginNet income ÷ Revenue | -14.2% | +42.9% |
| FCF MarginFCF ÷ Revenue | -13.9% | +8.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.3% | +12.0% |
| EPS Growth (YoY)Latest quarter vs prior year | — | 0.0% |
Valuation Metrics
| Metric | ARDXArdelyx, Inc. | ADMAADMA Biologics, I… |
|---|---|---|
| Market CapShares × price | $1.6B | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -25.19x | 19.22x |
| Forward P/EPrice ÷ next-FY EPS est. | 401.84x | 16.30x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 25.10x |
| Price / SalesMarket cap ÷ Revenue | 3.91x | 8.70x |
| Price / BookPrice ÷ Book value/share | 9.46x | 10.86x |
| Price / FCFMarket cap ÷ FCF | — | 33.71x |
Profitability & Efficiency
ADMA delivers a 48.6% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-37 for ARDX. ADMA carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARDX's 1.25x. On the Piotroski fundamental quality scale (0–9), ADMA scores 7/9 vs ARDX's 3/9, reflecting strong financial health.
| Metric | ARDXArdelyx, Inc. | ADMAADMA Biologics, I… |
|---|---|---|
| ROE (TTM)Return on equity | -36.7% | +48.6% |
| ROA (TTM)Return on assets | -11.6% | +36.8% |
| ROICReturn on invested capital | -10.8% | +37.7% |
| ROCEReturn on capital employed | -10.6% | +39.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | 1.25x | 0.24x |
| Net DebtTotal debt minus cash | $140M | -$21M |
| Cash & Equiv.Liquid assets | $68M | $103M |
| Total DebtShort + long-term debt | $208M | $82M |
| Interest CoverageEBIT ÷ Interest expense | -1.27x | 19.63x |
Total Returns (with DRIP)
A $10,000 investment in ADMA five years ago would be worth $64,339 today (with dividends reinvested), compared to $38,081 for ARDX. Over the past 12 months, ARDX leads with a +22.2% total return vs ADMA's -5.0%. The 3-year compound annual growth rate (CAGR) favors ADMA at 63.7% vs ARDX's 31.5% — a key indicator of consistent wealth creation.
| Metric | ARDXArdelyx, Inc. | ADMAADMA Biologics, I… |
|---|---|---|
| YTD ReturnYear-to-date | +6.5% | -12.9% |
| 1-Year ReturnPast 12 months | +22.2% | -5.0% |
| 3-Year ReturnCumulative with dividends | +127.4% | +338.6% |
| 5-Year ReturnCumulative with dividends | +280.8% | +543.4% |
| 10-Year ReturnCumulative with dividends | +170.7% | +227.8% |
| CAGR (3Y)Annualised 3-year return | +31.5% | +63.7% |
Risk & Volatility
ARDX is the less volatile stock with a 0.62 beta — it tends to amplify market swings less than ADMA's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARDX currently trades 78.0% from its 52-week high vs ADMA's 60.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARDXArdelyx, Inc. | ADMAADMA Biologics, I… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.62x | 1.10x |
| 52-Week HighHighest price in past year | $8.40 | $25.67 |
| 52-Week LowLowest price in past year | $3.21 | $13.50 |
| % of 52W HighCurrent price vs 52-week peak | +78.0% | +60.7% |
| RSI (14)Momentum oscillator 0–100 | 46.1 | 35.7 |
| Avg Volume (50D)Average daily shares traded | 4.1M | 1.8M |
Analyst Outlook
Wall Street rates ARDX as "Buy" and ADMA as "Buy". Consensus price targets imply 159.5% upside for ARDX (target: $17) vs 2.8% for ADMA (target: $16).
| Metric | ARDXArdelyx, Inc. | ADMAADMA Biologics, I… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $16.00 |
| # AnalystsCovering analysts | 16 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 100 | 432.78 | +332.8% |
| ADMA Biologics, Inc. (ADMA) | 100 | 589.23 | +489.2% |
ADMA Biologics, Inc. (ADMA) returned +543% over 5 years vs Ardelyx, Inc. (ARDX)'s +281%. A $10,000 investment in ADMA 5 years ago would be worth $64,339 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | $24M | $407M | +1595.3% |
| ADMA Biologics, Inc. (ADMA) | $11M | $426M | +3900.1% |
Ardelyx, Inc.'s revenue grew from $24M (2016) to $407M (2025) — a 37.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | -4.7% | -15.1% | -223.3% |
| ADMA Biologics, Inc. (ADMA) | -183.1% | 46.4% | +125.3% |
Ardelyx, Inc.'s net margin went from -5% (2016) to -15% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | -2.8 | -0.26 | +90.7% |
| ADMA Biologics, Inc. (ADMA) | -1.61 | 0.81 | +150.3% |
Ardelyx, Inc.'s EPS grew from $-2.80 (2016) to $-0.26 (2025).
Chart 5Free Cash Flow — 5 Years
Ardelyx, Inc. generated $-44M FCF in 2025 (+72% vs 2021). ADMA Biologics, Inc. generated $110M FCF in 2024 (+187% vs 2021).
ARDX vs ADMA: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ARDX or ADMA a better buy right now?
ADMA Biologics, Inc. (ADMA) offers the better valuation at 19.2x trailing P/E (16.3x forward), making it the more compelling value choice. Analysts rate Ardelyx, Inc. (ARDX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ARDX or ADMA?
On forward P/E, ADMA Biologics, Inc. is actually cheaper at 16.3x.
03Which is the better long-term investment — ARDX or ADMA?
Over the past 5 years, ADMA Biologics, Inc. (ADMA) delivered a total return of +543.4%, compared to +280.8% for Ardelyx, Inc. (ARDX). A $10,000 investment in ADMA five years ago would be worth approximately $64K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADMA returned +227.8% versus ARDX's +170.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ARDX or ADMA?
By beta (market sensitivity over 5 years), Ardelyx, Inc. (ARDX) is the lower-risk stock at 0.62β versus ADMA Biologics, Inc.'s 1.10β — meaning ADMA is approximately 77% more volatile than ARDX relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 24% versus 125% for Ardelyx, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — ARDX or ADMA?
ADMA Biologics, Inc. (ADMA) is the more profitable company, earning 46.4% net margin versus -15.1% for Ardelyx, Inc. — meaning it keeps 46.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 32.6% versus -10.1% for ARDX. At the gross margin level — before operating expenses — ARDX leads at 90.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ARDX or ADMA more undervalued right now?
On forward earnings alone, ADMA Biologics, Inc. (ADMA) trades at 16.3x forward P/E versus 401.8x for Ardelyx, Inc. — 385.5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARDX: 159.5% to $17.00.
07Which pays a better dividend — ARDX or ADMA?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ARDX or ADMA better for a retirement portfolio?
For long-horizon retirement investors, Ardelyx, Inc. (ARDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.62), +170.7% 10Y return). Both have compounded well over 10 years (ARDX: +170.7%, ADMA: +227.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ARDX and ADMA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.